Cargando…

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists

The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food inta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holst, Jens Juul, Rosenkilde, Mette Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308078/ https://www.ncbi.nlm.nih.gov/pubmed/32459834 http://dx.doi.org/10.1210/clinem/dgaa327

Ejemplares similares

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
por: Boer, Geke Aline, et al.
Publicado: (2020)

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
por: Lindquist, Peter, et al.
Publicado: (2022)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

Bariatric Surgery: It’s Not Just Incretins!
por: Ferraz-Bannitz, Rafael, et al.
Publicado: (2021)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

The Causal Relationship Between Sleep and Obesity: Novel Insights and Therapeutic Target
por: Wang, Jun, et al.
Publicado: (2022)

Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes
por: Mandøe, Mette Johannsen, et al.
Publicado: (2018)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
por: Holst, Jens Juul
Publicado: (2021)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight
por: DeBenedictis, Julia Nicole, et al.
Publicado: (2020)

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
por: Cena, Hellas, et al.
Publicado: (2020)

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2019)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

Editorial: Incretin agonists in the treatment of obesity
por: Sun, Xiaodong, et al.
Publicado: (2023)

GIP-induced vasodilation in human adipose tissue involves capillary recruitment
por: Asmar, Meena, et al.
Publicado: (2019)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Cohort Profile: The Stockholm Diabetes Prevention Programme (SDPP)
por: Gudjonsdottir, Hrafnhildur, et al.
Publicado: (2022)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Response to Letter to the Editor From Asadipooya: “Obesity and COVID-19: Mechanistic Insights From Adipose Tissue”
por: Yu, Lili, et al.
Publicado: (2022)

Longitudinal Metabolic Profiling of Maternal Obesity, Gestational Diabetes, and Hypertensive Pregnancy Disorders
por: Kivelä, Jemina, et al.
Publicado: (2021)

Altered Lipid Metabolism in Obese Women With Gestational Diabetes and Associations With Offspring Adiposity
por: Furse, Samuel, et al.
Publicado: (2022)

Estimated Association Between Cytokines and the Progression to Diabetes: 10-year Follow-Up From a Community-Based Cohort
por: Cho, Nam H, et al.
Publicado: (2019)

A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now
por: Cusi, Kenneth
Publicado: (2022)

Galectin-3 in NAFLD: Therapeutic Target or Noncausal Biomarker?
por: Soccio, Raymond E
Publicado: (2021)

New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
por: Garvey, W Timothy
Publicado: (2021)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Cohort Profile: The Danish Blood Donor Study
por: Erikstrup, Christian, et al.
Publicado: (2022)

Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability
por: Kim, Yeon-Sook, et al.
Publicado: (2020)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

Neurodevelopmental Disorders, Glycemic Control, and Diabetic Complications in Type 1 Diabetes: a Nationwide Cohort Study
por: Liu, Shengxin, et al.
Publicado: (2021)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
por: Boer, Geke Aline, et al.
Publicado: (2021)

Obesity, Thyroid Nodularity, and Thyroid Cancer: Epiphenomenon or Cause?
por: Bradley, David
Publicado: (2020)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bg6to2t5i4evou8lhe58c18l00